We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


BioInvent Signs Licensing Agreement with Mitsubishi Tanabe Pharma Corporation

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "BioInvent Signs Licensing Agreement with Mitsubishi Tanabe Pharma Corporation"

Listen with
Register for FREE to listen to this article
Thank you. Listen to this article using the player above.
Read time:
BioInvent International AB has announced that it has signed a license agreement with Mitsubishi Tanabe Pharma Corporation for the development of antibodies, up to five therapeutic targets, from BioInvent’s n-CoDeR® library.

Under the terms of the agreement, Mitsubishi Tanabe will be granted access to BioInvent’s discovery and development technology platform.

BioInvent will receive an undisclosed upfront access fee, annual maintenance fees as well as royalties on commercialized products and success-based milestone payments. The agreement follows on an existing research license and a feasibility study concluded earlier this year.

The n-CoDeR® library contains more than 20 billion (2 x 1010) highly diverse, fully human antibody fragments that have been created using BioInvent’s patented approach, generating antibodies with high affinity and selectivity.

Svein Mathisen, CEO of BioInvent, commented, “The signing of a second agreement for our n-CoDeR® library by a major Japanese pharmaceutical company validates further our proprietary antibody library. We look forward to working with Mitsubishi Tanabe and expanding our presence in the growing Japanese market.”